Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.
University of Oklahoma researchers have discovered one reason why the brain tumor glioblastoma is so aggressive.
Dxcover Limited on April 30 announced the presentation of real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer.
FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.
The European Medicines Agency approved Calquence (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant.
The National Cancer Institute approved the following clinical research studies last month.
Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.
An updated version of President Trump’s budget request published on May 2 comes as a disappointment for those who hoped that the White House would rethink the draconian cuts contained in an earlier, confidential version of the document that ended up being leaked to the press.
After nearly three decades of reviewing NCI-funded extramural projects and sometimes saving NCI from its own folly, the Board of Scientific Advisors has been terminated as part of the Trump administration’s drive to reduce the size of the federal government.
In the starkest opposition yet by Republicans to the Trump administration’s attacks on HHS agencies, senators from both parties sounded an alarm about the damage being done to biomedical research in the U.S.
